Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient.

Autor: García-Álvarez, Rosa María, Zapata-Cachafeiro, Maruxa, Visos-Varela, Irene, Rodríguez-Fernández, Almudena, Pintos-Rodríguez, Samuel, Piñeiro-Lamas, Maria, Herdeiro, Teresa M., Figueiras, Adolfo, Salgado-Barreira, Angel, Bugarín-González, Rosendo, Carracedo-Martínez, Eduardo, González-Barcala, Francisco J., Lema-Oreiro, Martina, Mallah, Narmeen, Portela-Romero, Manuel, Prieto-Campo, Angela, Saez, Marc, Taracido-Trunk, Margarita
Předmět:
Zdroj: Inflammopharmacology; Jun2024, Vol. 32 Issue 3, p1805-1815, 11p
Abstrakt: Objectives: To assess the impact of prior chronic treatment with angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin-receptor blockers (ARBs), both as a group and by active ingredient, on severity (risk of hospitalization and mortality), progression of and susceptibility to COVID-19. Methods: We conducted a multiple population-based case–control study in Galicia (north-west Spain). The study data were sourced from medical, administrative and clinical databases. We assessed: (1) risk of hospitalization, by selecting all patients hospitalized due to COVID-19 with PCR + as cases, and a random sample of subjects without a PCR + as controls; (2) COVID-19 mortality risk; (3) risk of disease progression; and (4) susceptibility to SARS-CoV-2, considering all patients with PCR + as cases, and the same subjects used in the previous model as controls. Adjusted odds ratios (aORs) were calculated. Results: ACEIs and ARBs were shown to decrease the risk of hospitalization (aOR = 0.78 [95%CI 0.69–0.89] and aOR = 0.80 [95%CI 0.72–0.90] respectively), risk of mortality (aOR = 0.71 [95%CI 0.52–0.98] and aOR = 0.69 [95%CI 0.52–0.91] respectively), and susceptibility to the virus (aOR = 0.88 [95%CI 0.82–0.94] and aOR = 0.92 [95%CI 0.86–0.97] respectively). By active ingredient: use of enalapril was associated with a significantly lower risk of hospitalization (aOR = 0.72 [95%CI 0.61–0.85]), mortality (aOR = 0.59 [95%CI 0.38–0.92]) and susceptibility to COVID-19 (aOR = 0.86 [95%CI 0.79–0.94]); and use of candesartan was associated with a decreased risk of hospitalization (aOR = 0.76 [95%CI 0.60–0.95]), mortality (aOR = 0.36 [95%CI 0.17–0.75]) and disease progression (aOR = 0.73 [95%CI 0.56–0.95]). Conclusion: This large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: